Clinical trial
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or…
NCT00004223 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00004223 |
|---|---|
| Title | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer |
| Official title | Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine hydrochloride |
| Start date | Feb 24, 2000 |
| Primary completion | Oct 1, 2002 |
| First posted | Feb 25, 2004 |
| Last update posted | Jun 18, 2023 |
| Countries | Puerto Rico, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: